Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


18.04.2017

1 Am J Clin Pathol
1 Anticancer Res
1 BJU Int
1 BMC Cancer
1 Br J Cancer
2 Br J Radiol
1 Clin Cancer Res
1 Eur Radiol
4 Eur Urol
3 J Nucl Med
1 J Urol
1 JAMA
2 Nat Rev Urol
1 Oncogene
1 PLoS One
2 Prog Urol
3 Prostate
2 Radiology
2 Semin Oncol
2 Ther Adv Urol
10 Urol Int
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Pathol

  1. VOLLMER RT
    Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death.
    Am J Clin Pathol. 2017;147:273-277.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


    BJU Int

  3. GANDAGLIA G, Fossati N, Dell'Oglio P, Montorsi F, et al
    Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?
    BJU Int. 2017;119:652-653.
    PubMed     Text format    


    BMC Cancer

  4. NGOLLO M, Lebert A, Daures M, Judes G, et al
    Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression.
    BMC Cancer. 2017;17:261.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. JANSSEN A, Verkleij CP, van der Vlist A, Mathijssen RH, et al
    Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Br J Radiol

  6. CHAN J, Carver A, Brunt JN, Vinjamuri S, et al
    Effect of androgen deprivation therapy on intra-prostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy.
    Br J Radiol. 2016 Dec 20:20160818.
    PubMed     Text format     Abstract available

  7. HARVEY H, Orton MR, Morgan VA, Parker C, et al
    Volumetry of the Dominant Intraprostatic Tumour Lesion: Intersequence and Interobserver Differences on Multiparametric MRI.
    Br J Radiol. 2017 Jan 5:20160416. doi: 10.1259/bjr.20160416.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  8. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
    Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
    PubMed     Text format     Abstract available


    Eur Radiol

  9. OVERDUIN CG, Jenniskens SF, Sedelaar JP, Bomers JG, et al
    Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes.
    Eur Radiol. 2017 Apr 13. doi: 10.1007/s00330-017-4833.
    PubMed     Text format     Abstract available


    Eur Urol

  10. KLEIN EA, Chait A, Hafron JM, Kernen KM, et al
    The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary
    Eur Urol. 2017 Apr 7. pii: S0302-2838(17)30236.
    PubMed     Text format     Abstract available

  11. RADTKE JP, Wiesenfarth M, Kesch C, Freitag MT, et al
    Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30267.
    PubMed     Text format     Abstract available

  12. KARNES RJ, Choeurng V, Ross AE, Schaeffer EM, et al
    Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264.
    PubMed     Text format     Abstract available

  13. WALKER SM, Knight LA, McCavigan AM, Logan GE, et al
    Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30238.
    PubMed     Text format     Abstract available


    J Nucl Med

  14. YOUNG JD, Abbate V, Imberti C, Meszaros LK, et al
    68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.191882. doi: 10.2967/jnumed.117.191882.
    PubMed     Text format     Abstract available

  15. FENDLER WP, Calais J, Allen-Auerbach M, Bluemel C, et al
    68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190827. doi: 10.2967/jnumed.117.190827.
    PubMed     Text format     Abstract available

  16. KESCH C, Kratochwil C, Mier W, Kopka K, et al
    Gallium-68 or Fluorine-18 for prostate cancer imaging?
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190157. doi: 10.2967/jnumed.117.190157.
    PubMed     Text format     Abstract available


    J Urol

  17. NATARAJAN S, Jones TA, Priester AM, Geoghegan R, et al
    Focal Laser Ablation of Prostate Cancer: Feasibility of MRI/US Fusion for Guidance.
    J Urol. 2017 Apr 7. pii: S0022-5347(17)45433-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    JAMA

  18. BIBBINS-DOMINGO K, Grossman DC, Curry SJ
    The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.
    JAMA. 2017 Apr 11. doi: 10.1001/jama.2017.4413.
    PubMed     Text format    


    Nat Rev Urol

  19. FENNER A
    Prostate cancer: Twist and Skp2 castration resistance.
    Nat Rev Urol. 2017 Apr 11. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  20. STONE L
    Prostate cancer: Peptidomimetics have potential.
    Nat Rev Urol. 2017 Apr 11. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncogene

  21. ZONI E, Chen L, Karkampouna S, Granchi Z, et al
    CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    PLoS One

  22. MARTINEZ-MARIN D, Jarvis C, Nelius T, de Riese W, et al
    PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.
    PLoS One. 2017;12:e0174968.
    PubMed     Text format     Abstract available


    Prog Urol

  23. MONDET F, Alimi JC, Boyer C
    [Cancer plans apply to surgical treatment of prostate cancer: A geographically isolated center balance].
    Prog Urol. 2017 Apr 6. pii: S1166-7087(17)30046.
    PubMed     Text format     Abstract available

  24. ROZET F, Roupret M, Hennequin C, Massard C, et al
    [Management of a progressing prostate cancer: results of a national study].
    Prog Urol. 2017 Apr 6. pii: S1166-7087(17)30022.
    PubMed     Text format     Abstract available


    Prostate

  25. GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
    Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
    Prostate. 2016;76:917-26.
    PubMed     Text format     Abstract available

  26. SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
    Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Prostate. 2016;76:905-16.
    PubMed     Text format     Abstract available

  27. NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
    Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
    Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
    PubMed     Text format     Abstract available


    Radiology

  28. TAMADA T, Prabhu V, Li J, Babb JS, et al
    Prostate Cancer: Diffusion-weighted MR Imaging for Detection and Assessment of Aggressiveness-Comparison between Conventional and Kurtosis Models.
    Radiology. 2017 Apr 10:162321. doi: 10.1148/radiol.2017162321.
    PubMed     Text format     Abstract available

  29. SABOURI S, Chang SD, Savdie R, Zhang J, et al
    Luminal Water Imaging: A New MR Imaging T2 Mapping Technique for Prostate Cancer Diagnosis.
    Radiology. 2017 Apr 10:161687. doi: 10.1148/radiol.2017161687.
    PubMed     Text format     Abstract available


    Semin Oncol

  30. PARNES HL
    Commentary: Prostate cancer screening-A long run for a short slide.
    Semin Oncol. 2017;44:57-59.
    PubMed     Text format    

  31. STEWART RW, Lizama S, Peairs K, Sateia HF, et al
    Screening for prostate cancer.
    Semin Oncol. 2017;44:47-56.
    PubMed     Text format     Abstract available


    Ther Adv Urol

  32. HEGEMANN M, Bedke J, Stenzl A, Todenhofer T, et al
    Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.
    Ther Adv Urol. 2017;9.
    PubMed     Text format     Abstract available

  33. AOUN F, Bourgi A, Ayoub E, El Rassy E, et al
    Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.
    Ther Adv Urol. 2017;9.
    PubMed     Text format     Abstract available


    Urol Int

  34. CHOI H, Cho S, Bae JH, Lee SE, et al
    Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
    Urol Int. 2017 Apr 11. doi: 10.1159/000454886.
    PubMed     Text format     Abstract available

  35. SCHIFFMANN J, Haese A, Lenz J, Heinzer H, et al
    Differences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center.
    Urol Int. 2016;97:8-15.
    PubMed     Text format     Abstract available

  36. ROSENKRANTZ AB, Lepor H, Huang WC, Taneja SS, et al
    Practical Barriers to Obtaining Pre-Biopsy Prostate MRI: Assessment in Over 1,500 Consecutive Men Undergoing Prostate Biopsy in a Single Urologic Practice.
    Urol Int. 2016;97:247-8.
    PubMed     Text format    

  37. ANGULO JC, Lopez JI, Dorado JF, Sanchez-Chapado M, et al
    A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy.
    Urol Int. 2016;97:16-25.
    PubMed     Text format     Abstract available

  38. SCHIFFMANN J, Larcher A, Sun M, Tian Z, et al
    Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice - Analysis of Surveillance, Epidemiology, and End Results Database.
    Urol Int. 2017;98:40-48.
    PubMed     Text format     Abstract available

  39. GUNZEL K, Haas M, Maxeiner A, Stephan C, et al
    Predictive Parameters Identifying Men Eligible for a Sole MRI/Ultrasound Fusion-Guided Targeted Biopsy without an Additional Systematic Biopsy.
    Urol Int. 2017;98:15-21.
    PubMed     Text format     Abstract available

  40. HAAS M, Gunzel K, Miller K, Hamm B, et al
    Is the Ellipsoid Formula the New Standard for 3-Tesla MRI Prostate Volume Calculation without Endorectal Coil?
    Urol Int. 2017;98:49-53.
    PubMed     Text format     Abstract available

  41. KLEIN J, de Gorski A, Benamran D, Vallee JP, et al
    Transrectal Ultrasound-Guided Prostate Biopsy for Cancer Detection: Performance of 2D-, 3D- and 3D-MRI Fusion Targeted Techniques.
    Urol Int. 2017;98:7-14.
    PubMed     Text format     Abstract available

  42. ORBERGER M, Palisaar J, Roghmann F, Mittelstadt L, et al
    Association between the Surgical Apgar Score and Perioperative Complications after Radical Prostatectomy.
    Urol Int. 2017;98:61-70.
    PubMed     Text format     Abstract available

  43. MENDEZ-RUBIO S, Salinas Casado J, Virseda Chamorro M, Gutierrez Martin P, et al
    Post Pelvic Radiotherapy Affectation of the Lower Urinary Tract Peripheral Innervation in Men.
    Urol Int. 2017;98:85-88.
    PubMed     Text format     Abstract available


    Urology

  44. GUERRIOS-RIVERA L, Howard L, Frank J, De Hoedt A, et al
    Is BMI the Best Adiposity Measure for Prostate Cancer Risk? Results From a VA Biopsy Cohort.
    Urology. 2017 Apr 10. pii: S0090-4295(17)30347.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: